New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users

Drug and Alcohol Dependence

Volumn 54, Issue 2, 1999, Pages 145-154

  Krol, Anneke ^a   Flynn, Colin ^b   Vlahov, David ^b   Miedema, Frank ^c,d   Coutinho, Roel A ^a,d   Van Ameijden, Erik J C ^a  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTRAL LABORATORY   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

CD4+ lymphocyte decline; Drug users; Heroin; HIV; Substance abuse

Indexed keywords

CD4 ANTIGEN; DIAMORPHINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; SEROCONVERSION; UNITED STATES; VIROGENESIS;

ADULT; BALTIMORE; CD4-POSITIVE T-LYMPHOCYTES; COCAINE; COHORT STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE PROGRESSION; FEMALE; HEROIN; HIV INFECTIONS; HUMANS; IMMUNOCOMPETENCE; LINEAR MODELS; LYMPHOCYTE COUNT; MALE; NETHERLANDS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0032966779     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(98)00158-6     Document Type: Article

References (45)

1. Alcabes P., Schoenbaum E.E., Klein R.S. Correlates of the rate of decline of CD4+ lymphocytes among injection drug users infected with the human immunodeficiency virus. Am. J. Epidemiol. 137:1993;989-1000.
2. Alcabes P., Friedland G. Injection drug use and human immunodeficiency virus infection. Rev. Clin. Infect. Dis. 20:1995;1467-1479.
3. Anthony J.C., Vlahov D., Celentano D.D.et al. Self-report interview data for a study of HIV-1 infection among intravenous drug users: description of methods and preliminary evidence on validity. J. Drug Issues. 21:1991;739-757.
4. Centers for Disease Control and Prevention, 1992. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR, 41 (No. RR-17):-17), 1-19.
5. Crum R.M., Galai N., Cohn S., Celentano D.D., Vlahov D. Alcohol use and T-lymphocyte subsets among injection drug users with HIV-1 infection: a prospective analysis. Alcoholism, Clin. Exp. Res. 20:1996;364-371.
6. Diggle, P.J., Liang, K.Y., Zeger, S.L., 1994. Analysis of Longitudinal Data. Clarendon Press, Oxford.
7. Donahoe, R.M., Falek, A., Madden, J.J., Nicholson, J.K.A., Bokos, P., Gallegos, K., and Veit, R., 1991. Effects of cocaine and other drugs of abuse on immune function. In: Friedman, H., et al. (eds.), Drugs of Abuse, Immunity, and Immunodeficiency. Plenum Press, New York, pp. 143-150.
8. Donahoe R.M., Byrd L.D., McClure H.M., Fultz P., Brantley M., Marsteller F., Ansari A.A., Wenzel D., Aceto M. Consequences of opiate-dependency in a monkey model of AIDS. Rev. Adv. Exp. Med. Biol. 335:1993;21-28.
9. Dorrucci M., Pezzotti P., Phillips A.N., Lepri A.C., Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J. Infect. Dis. 172:1995;1503-1508.
10. Dorrucci M., Rezza G., Vlahov D., Pezzotti P., Sinicco A., Nicolosi A., Lazzarin A., Galai N., Gafà S., Pristerà R., Angarano G. Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study. AIDS. 9:1995;597-604.
11. Furci L., Beretta A., Siccardi A., Lazzarin A., Confetti C., Magnani Z., Scarpellini P., Lopalco L., Burastero S. Human immunodeficiency virus type 1 glycoprotein 120-specific T lymphocytes provide intermolecular help for anti-CD4 autoantibody production in exposed uninfected subjects. AIDS Res. Hum. Retroviruses. 13:1997;1461-1469.
12. Galai N., Muñoz A., Chen K., Carey V.J., Chmiel J., Zhou S.Y.J. Tracking of markers and onset of disease among HIV-1 seroconverters. Stat. Med. 12:1993;2133-2145.
13. Galai N., Vlahov D., Margolick J.B., Chen K., Graham N.M.H., Muñoz A. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:1995;66-74.
14. Hershow R.C., Galai N., Fukuda K., Graber J., Vlahov D., Rezza G., Klein R.S., Des Jarlais D.C., Vitek C., Khabbaz R.F., Freels S., Zuckerman R., Pezzotti P., Kaplan J.E. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type I disease progression in injection drug users. J. Infect. Dis. 174:1996;309-317.
15. Lang W., Perkins H., Anderson R.et al. Patterns of T-lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J. Acquir. Immune Defic. Syndr. 2:1989;63-69.
16. Latkin C.A., Vlahov D., Anthony J.C. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction. 88:1993;517-526.
17. Lyles C.M., Margolick J.B., Astemborski J., Graham N.M.H., Anthony J.C., Hoover D.R., Vlahov D. The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users. AIDS. 11:1997;1255-1262.
18. Manoff S.B., Farzadegan H., Muñoz A., Astemborski J.A., Vlahov D., Rizzo R.T., Solomon L., Graham N.M.H. The effect of latent Mycobacterium tuberculosis infection on human immunodeficiency virus (HIV) disease progression and HIV RNA load among injecting drug users. J. Infect. Dis. 174:1996;299-308.
19. Margolick J.B., Muñoz A., Vlahov D.et al. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. J. Am. Med. Assoc. 267:1992;1631-1636.
20. Margolick J.B., Donnenberg A.D., Muñoz A.et al. Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3-populations suggest regulatory responses linked to loss of CD4. J. Acquir. Immune Defic. Syndr. 6:1993;153-161.
21. Margolick J.B., Muñoz A., Vlahov D., Astemborski J., Solomon L., He X., Nelson K.E., Saah A.J. Direct comparison of the relationship between clinical outcome and change in CD4+ lymphocytes in human immunodeficiency virus-positive homosexual men and injecting drug users. Arch. Intern. Med. 154:1994;869-875.
22. Margolick J.B., Muñoz A., Donnenberg A.D., Park L.P., Galai N., Giorgi J.V., O'Gorman M.R., Ferbas J. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat. Med. 1:1995;674-680.
23. Mazzoli S., Trabattoni D., Lo Caputo S., Piconi S., Ble C., Meacci F., Ruzzante S., Salvi A., Semplici F., Longhi R., Fusi M.L., Tofani N., Biasin M., Villa M.L., Mazzotta F., Clerici M. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3:1997;1250-1257.
24. Mientjes G.H.C., Miedema F., van Ameijden E.J.C., van den Hoek J.A.R., Schellekens P.T.A., Roos M.T.L., Coutinho R.A. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS. 5:1991;35-41.
25. Mientjes G.H.C., van Ameijden E.J.C., van den Hoek J.A.R., Goudsmit J., Miedema F., Coutinho R.A. Progression of HIV infection among injecting drug users: indications for a lower rate of progression among those who have frequently borrowed injecting equipment. AIDS. 7:1993;1363-1370.
26. Montella F., Di Sora F., Perucci C.A., Abeni D.D., Recchia O. T-lymphocyte subsets in intravenous drug users with HIV-1 infection. J. Am. Med. Assoc. 268:1992;2516-2517.
27. Muñoz A., Vlahov D., Solomon L., Margolick J.B., Bareta J.C., Cohn S., Astemborski J., Nelson K.E. Prognostic indicators for development of AIDS among intravenous drug users. J. Acquir. Immune Defic. Syndr. 5:1992;694-700.
28. Peterson P.K., Sharp B.M., Gekker G., Portoghese P.S., Sannerud K., Balfour H.H. Morphine promotes the growth of HIV-1 in human peripheral blood monocuclear cell cocultures. AIDS. 4:1990;869-973.
29. Pezzotti P., Galai N., Muñoz A., Vlahov D., Rezza G. Decremento dei linfociti CD4+ nell'infezione da HIV: uno studio longitudinale su 941 individui con data di sieroconversione nota. Giornale Italiano dell. AIDS. 5:1994;93-100.
30. Pezzotti P., Phillips A.N., Dorrucci M., Cozzi Lepri A., Galai N., Vlahov D., Rezza G. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. HIV Italian Seroconversion Study Group. Br. Med. J. 313:1996;583-586.
31. Pillai R., Nair B.S., Watson R.R. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Rev. Arch. Toxicol. 65:1991;609-617.
32. Prins M., Veugelers P.J. Comparison of progression and nonprogression in 418 injecting drug users and 422 homosexual men with documented dates of HIV-1 seroconversion. AIDS. 11:1997;621-631.
33. Risdahl J.M., Peterson P.K., Chao C.C., Pijoan C., Molitor T.W. Effects of morphine dependence on the pathogenesis of swine herpes virus infection. J. Infect. Dis. 167:1993;1281-1287.
34. Ronald P.J.M., Robertson J.R., Elton R.A. Continued drug use and other cofactors for progression to AIDS among injecting drug users. AIDS. 8:1994;339-343.
35. Samuels J.F., Vlahov D., Anthony J.C., Chaisson R.E. Measurement of HIV risk behaviors among intravenous drug users. Rev. Br. J. Addict. 87:1992;417-428.
36. SAS Institute, 1996. SAS/STAT Software: Changes enhancements through release 6.11. SAS Institute.
37. Selwyn P.A., Alcabes P., Hartel D., Buono D., Schoenbaum E.E., Klein R.S., Davenny K., Friedland G.H. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection [published erratum appears in New Engl. J. Med. 1993 Mar 4;328(9), 671]. New Engl. J. Med. 327:1992;1697-1703.
38. Siddiqui N.S., Brown L.S., Makuch R.W. Short-term declines in CD4 levels associated with cocaine use in HIV-1 seropositive, minority injecting drug users. J. Natl. Med. Assoc. 85:1993;293-296.
39. Sinicco A., Raiteri R., Sciandra M., Bertone C., Lingua A., Salassa B., Gioannini P. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand. J. Infect. Dis. 29:1997;111-115.
40. Spijkerman I.J.B., Langendam M.W., Veugelers P.J., van Ameijden E.J.C., Keet I.P.M., Geskus R.B., van den Hoek J.A.R., Coutinho R.A. Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology. 7:1996;571-577.
41. van den Hoek J.A.R., Coutinho R.A., van Haastrecht H.J.A., van Zadelhoff A.W., Goudsmit J. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS. 2:1988;55-60.
42. van Rood J.J., Claas F.H. The influence of allogeneic cells on the human T and B cell repertoire. Science. 248:1990;1388-1393.
43. Veugelers P.J., Kaldor J.M., Strathdee S.A., Page-Shafer K.A., Schechter M.T., Coutinho R.A., Keet I.P.M., van Griensven G.J.P. Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men. J. Infect. Dis. 176:1997;112-117.
44. Veyries M.L., Sinet M., Desforges B., Rouveix B. Effects of morphine on the pathogenesis of murine friend retrovirus infection. J. Pharmacol. Exp. Ther. 272:1995;498-504.
45. Vlahov D., Anthony J.C., Muñoz A., Margolick J., Nelson K.E., Celentano D.D., Solomon L., Polk B.F. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res. Monograph Ser. 109:1991;75-100.